Collectively, SUMMIT offers high‐quality evidence that targeting obesity and metabolic dysfunction with a dual GIP/GLP‐1 agonist can modify the disease trajectory in HFpEF, reducing HF events while improving exercise capacity and quality of life. Here, GIP is linked to obesity disorder.